- Alternative Therapies
- Blood, Heart and Circulation
- Bones and Muscles
- Brain and Nerves
- Cancers
- Child health
- Cosmetic Surgery
- Digestive System
- Disorders and Conditions
- Drugs Approvals and Trials
- Environmental Health
- Ear, Nose and Throat
- Eyes and Vision
- Female Reproductive
- Genetics and Birth Defects
- Geriatrics and Aging
- Immune System
- Infections
- Kidneys and Urinary System
- Life style and Fitness
- Lungs and Breathing
- Male Reproductive
- Medical Breakthroughs
- Mental Health and Behavior
- Metabolic Problems
- Oral and Dental Health
- Pregnancy and Childbirth
- Public Health and Safety
- Skin, Hair and Nails
- Substance Abuse
- Surgery and Rehabilitation
Toward new medications for chronic brain diseases
A needle-in-the-haystack search through nearly 390,000 chemical compounds had led scientists to a substance that can sneak through the protective barrier surrounding the brain with effects promising for new drugs for Parkinson's and Huntington's disease. They report on the substance, which blocks formation of cholesterol in the brain, in the journal, ACS Chemical Biology.
Aleksey G. Kazantsev and colleagues previously discovered that blocking cholesterol formation in the brain could protect against some of the damage caused by chronic brain disorders like Parkinson's disease. Several other studies have suggested that too much cholesterol may kill brain cells in similar neurodegenerative diseases. So they launched a search for a so-called "small molecules" — substances ideal for developing into medicines — capable of blocking formation of cholesterol.
They describe discovery of a small molecule that blocks the activity of a key protein involved in cholesterol production. It successfully lowered cholesterol levels in isolated nerve cells and brain slices from mice. If the molecule proves to be a good target for developing new drugs, the scientists note, "it could have a broader application in other neurological conditions, such as Alzheimer's disease, for which modulation of cholesterol and other associated metabolic pathways might be of therapeutic benefit."
The authors acknowledge funding from the Carmen Foundation, the RJG Foundation, the Michael J. Fox Foundation for Parkinson's Research, the CHDI Foundation, the Ecole Polytechnique Federale de Lausanne, and the Swiss National Science Foundation.
Contact: Michael Bernstein
m_bernstein@acs.org
202-872-6042
American Chemical Society



del.icio.us
Digg